IPO Databook: Guangzhou Novaken Pharm (HK) - Jul 2026

172 Views26 Jul 2026 10:19

SUMMARY

Founded in 2007, Guangzhou Novaken Pharm is a clinical-stage pharmaceutical company developing modified new drugs using alternative formulations and drug-delivery technologies.
DHMP is the first dissolving microneedle drug patch approved for clinical trials in China and the only one to Phase II.
Net current liabilities were (RMB573,269) as at May 31, 2026, with a current ratio of 0.2.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream